In fact, the levels of high-molecular-weight species of tau in platelets have been suggested to have diagnostic sensitivity and specificity of approximately 70% in AD patients, further supporting the utility of peripheral tau as a biomarker for CNS disorders [27]. The gene discussed is MAPT; the disease is central nervous system disorder.